TWI348468B - Process for preparing amino crotonyl compounds - Google Patents

Process for preparing amino crotonyl compounds

Info

Publication number: TWI348468B
Authority: TW; Taiwan
Prior art keywords: preparing amino; crotonyl compounds; compounds; amino crotonyl; preparing
Prior art date: 2003-10-17

Application number

TW093131395A

Other languages

English (en)

Other versions

TW200526644A (en

Inventor

Rainer Soyka

Werner Rall

Juergen Schnaubelt

Peter Sieger

Christian Kulinna

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2004-10-15

Publication date

2011-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34428508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI348468(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-15 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2005-08-16 Publication of TW200526644A publication Critical patent/TW200526644A/zh

2011-09-11 Application granted granted Critical

2011-09-11 Publication of TWI348468B publication Critical patent/TWI348468B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TW093131395A 2003-10-17 2004-10-15 Process for preparing amino crotonyl compounds TWI348468B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10349113A DE10349113A1 (de)	2003-10-17	2003-10-17	Verfahren zur Herstellung von Aminocrotonylverbindungen

Publications (2)

Publication Number	Publication Date
TW200526644A TW200526644A (en)	2005-08-16
TWI348468B true TWI348468B (en)	2011-09-11

Family

ID=34428508

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW093131395A TWI348468B (en)	2003-10-17	2004-10-15	Process for preparing amino crotonyl compounds
TW099147116A TWI373470B (en)	2003-10-17	2004-10-15	Process for preparing amino crotonyl compounds

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW099147116A TWI373470B (en)	2003-10-17	2004-10-15	Process for preparing amino crotonyl compounds

Country Status (35)

Country	Link
US (2)	US20050085495A1 (zh)
EP (2)	EP2508521B2 (zh)
JP (2)	JP4594317B2 (zh)
KR (2)	KR101282812B1 (zh)
CN (2)	CN1867564B (zh)
AR (1)	AR046118A1 (zh)
AU (2)	AU2004281938B2 (zh)
BR (2)	BR122013033343B8 (zh)
CA (2)	CA2759063C (zh)
CY (2)	CY1114866T1 (zh)
DE (1)	DE10349113A1 (zh)
DK (2)	DK2508521T4 (zh)
EA (1)	EA016624B1 (zh)
EC (1)	ECSP066509A (zh)
ES (2)	ES2440466T3 (zh)
HK (1)	HK1095817A1 (zh)
HR (2)	HRP20160246T4 (zh)
HU (1)	HUE028254T2 (zh)
IL (2)	IL174951A (zh)
ME (1)	ME00341B (zh)
MX (2)	MX338920B (zh)
MY (2)	MY155425A (zh)
NO (2)	NO333971B1 (zh)
NZ (2)	NZ547154A (zh)
PE (2)	PE20050965A1 (zh)
PL (2)	PL1678165T3 (zh)
PT (2)	PT1678165E (zh)
RS (3)	RS53398B (zh)
SG (1)	SG139743A1 (zh)
SI (2)	SI2508521T2 (zh)
TW (2)	TWI348468B (zh)
UA (2)	UA91006C2 (zh)
UY (2)	UY28559A1 (zh)
WO (1)	WO2005037824A2 (zh)
ZA (1)	ZA200602234B (zh)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ302365B6 (cs)	1999-06-21	2011-04-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg.	Bicyklické heterocyklické slouceniny, farmaceutický prostredek obsahující tyto slouceniny, jejich použití a zpusob výroby
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) *	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
KR100832594B1 (ko) *	2005-11-08	2008-05-27	한미약품 주식회사	다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
DK1948180T3 (da)	2005-11-11	2013-05-27	Boehringer Ingelheim Int	Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
ES2397181T3 (es) *	2006-01-26	2013-03-05	Boehringer Ingelheim International Gmbh	Procedimiento para preparar derivados de quinazolina sustituida con aminocrotonilamino
SI2068880T1 (sl)	2006-09-18	2012-08-31	Boehringer Ingelheim Int	Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
UY31867A (es) *	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
JP2012515184A (ja)	2009-01-14	2012-07-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	大腸がんの治療方法
RU2011141121A (ru)	2009-03-11	2013-04-20	Окленд Юнисервисиз Лимитед	Пролекарственные формы ингибиторов киназ и их применение в терапии
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
CN102711472B (zh) *	2009-07-02	2015-12-02	江苏康缘药业股份有限公司	含磷的喹唑啉化合物及其使用方法
LT2451445T (lt)	2009-07-06	2019-06-25	Boehringer Ingelheim International Gmbh	Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
WO2011069962A1 (en)	2009-12-07	2011-06-16	Boehringer Ingelheim International Gmbh	Bibw 2992 for use in the treatment of triple negative breast cancer
US20120107304A1 (en) *	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
DK2608792T3 (en)	2010-08-26	2018-01-15	Boehringer Ingelheim Int	PROCEDURES FOR SUBMITTING AN EGFR INHIBITOR.
WO2012121764A1 (en)	2010-11-25	2012-09-13	Ratiopharm Gmbh	Novel salts and polymorphic forms of afatinib
SG10201913982WA (en)	2011-03-04	2020-03-30	Newgen Therapeutics Inc	Alkyne Substituted Quinazoline Compound And Methods Of Use
CN102731485B (zh) *	2011-04-02	2016-06-15	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
WO2012155339A1 (zh) *	2011-05-17	2012-11-22	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20170079444A1 (en) *	2011-09-22	2017-03-23	Future Foam, Inc.	Enhanced washable mattress topper
WO2013052157A1 (en)	2011-10-06	2013-04-11	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
CN103073539B (zh) *	2011-10-26	2016-05-11	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
JP2015524400A (ja)	2012-07-19	2015-08-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
EP2951171A1 (en)	2013-02-01	2015-12-09	Boehringer Ingelheim International GmbH	Radiolabeled quinazoline derivatives
CN103254156B (zh) *	2013-05-10	2015-08-26	苏州明锐医药科技有限公司	阿法替尼中间体的制备方法
WO2014180271A1 (zh) *	2013-05-10	2014-11-13	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
CN103242303B (zh) *	2013-05-16	2015-03-25	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN103288808B (zh) *	2013-05-16	2015-11-11	苏州明锐医药科技有限公司	一种阿法替尼的制备方法
WO2015007206A1 (zh) *	2013-07-16	2015-01-22	杭州普晒医药科技有限公司	阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
CN104513229A (zh) *	2013-09-28	2015-04-15	正大天晴药业集团股份有限公司	喹唑啉衍生物及其制备方法
CN104710413B (zh) *	2013-12-16	2019-05-03	江苏豪森药业集团有限公司	二马来酸阿法替尼的制备方法
CN104744445A (zh) *	2013-12-30	2015-07-01	广东东阳光药业有限公司	一种酪氨酸激酶抑制剂的晶型
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015103456A1 (en) *	2014-01-02	2015-07-09	Teva Pharmaceuticals International Gmbh	Crystalline forms of afatinib di-maleate
CN104803992A (zh) *	2014-01-25	2015-07-29	广东东阳光药业有限公司	阿法替尼盐的晶型
WO2016001844A1 (en) *	2014-06-30	2016-01-07	Sun Pharmaceutical Industries Limited	Amorphous form of afatinib dimaleate
CN105315263B (zh) *	2014-07-30	2018-11-27	正大天晴药业集团股份有限公司	阿法替尼中间体的合成方法
WO2016027243A1 (en) *	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Novel solid state forms of afatinib dimaleate
US10011591B2 (en) *	2014-10-01	2018-07-03	Sun Pharmaceutical Industries Limited	Crystalline form of afatinib dimaleate
CN105534920B (zh) *	2014-10-29	2020-07-10	江苏豪森药业集团有限公司	一种药物组合物及其制备方法
CN104402872B (zh) *	2014-11-14	2016-08-24	广东东阳光药业有限公司	一种结晶除杂方法
CN104447713B (zh) *	2014-11-18	2019-03-29	江苏奥赛康药业股份有限公司	阿法替尼化合物的制备方法
EP3023421A1 (en) *	2014-11-21	2016-05-25	Sandoz Ag	Crystalline forms of afatinib dimaleate
CN104529800B (zh) *	2014-12-08	2017-01-25	重庆威鹏药业有限公司	反式‑4‑二甲基氨基巴豆酸及盐的制备方法
CN105801567A (zh) *	2014-12-31	2016-07-27	徐州万邦金桥制药有限公司	一种双马来酸阿法替尼的纯化方法
CN105801568B (zh) *	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
CN107406430B (zh)	2015-03-20	2019-04-26	正大天晴药业集团股份有限公司	喹唑啉衍生物的盐及其制备方法
KR20180003542A (ko) *	2015-04-17	2018-01-09	헤테로 랩스 리미티드	아파티닙과 그 염의 다형체 및 퀴나졸린일 유도체 제조 방법
CN105859641B (zh) *	2015-05-05	2018-11-16	杭州华东医药集团新药研究院有限公司	喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN104892584B (zh) *	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
AU2016276426B2 (en) *	2015-06-12	2019-12-05	Fresenius Kabi Oncology Ltd.	Polymorphic forms of Afatinib free base and Afatinib dimaleate
CN104926800A (zh) *	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法
CN105175331B (zh) *	2015-08-14	2019-04-26	江苏苏中药业集团股份有限公司	一种egfr类分子靶向抗肿瘤药物的制备方法
KR20180066039A (ko)	2015-08-21	2018-06-18	프레세니어스 카비 온콜로지 리미티드	아파티닙을 포함하는 약학적 조성물
WO2017093789A1 (en) *	2015-12-03	2017-06-08	Mylan Laboratories Ltd.	Polymorphic forms of afatinib dimaleate
CN106831733B (zh) *	2015-12-07	2021-05-11	海南先声药业有限公司	阿法替尼顺式异构体的制备方法与应用
CN106866641A (zh) *	2015-12-11	2017-06-20	河北神威药业有限公司	一种阿法替尼的精制方法
CN108430990B (zh) *	2015-12-25	2020-08-25	山东轩竹医药科技有限公司	喹唑啉衍生物的晶体及其制备方法
CN106916147A (zh) *	2015-12-25	2017-07-04	中美华世通生物医药科技（武汉）有限公司	化合物及其制备方法和用途
CN105669658B (zh) *	2016-04-05	2018-06-29	北京民康百草医药科技有限公司	一种阿法替尼的精制方法
CN107488153B (zh) *	2016-06-10	2020-06-23	山东新时代药业有限公司	一种阿法替尼中间体化合物
CN107488194B (zh) *	2016-06-10	2021-07-30	山东新时代药业有限公司	一种阿法替尼中间体及其制备方法
CN107488172B (zh) *	2016-06-10	2020-06-12	山东新时代药业有限公司	一种阿法替尼的制备方法
CN107488171B (zh) *	2016-06-10	2020-08-28	山东新时代药业有限公司	一种阿法替尼制备方法
CN106243092B (zh) *	2016-07-28	2019-02-15	南京臣功制药股份有限公司	一种高选择性制备马来酸阿法替尼的方法
KR20230145496A (ko)	2016-11-17	2023-10-17	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
EP3606916A1 (en)	2017-04-06	2020-02-12	Johnson Matthey Public Limited Company	Novel forms of afatinib dimaleate
CN108358900A (zh) *	2018-03-30	2018-08-03	东北制药集团股份有限公司	一种阿法替尼及其马来酸盐的制备方法
KR20190141607A (ko)	2018-06-14	2019-12-24	주식회사 에이티파머	알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제
KR102257913B1 (ko)	2018-07-17	2021-05-28	주식회사 에이티파머	알로페론을 포함하는 폐섬유증 치료용 조성물
CN109824657A (zh) *	2019-03-26	2019-05-31	石药集团中奇制药技术（石家庄）有限公司	一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110563710B (zh) *	2019-09-21	2020-05-19	广东安诺药业股份有限公司	一种马来酸阿法替尼的制备方法
CN110590754A (zh) *	2019-09-21	2019-12-20	广东安诺药业股份有限公司	一种马来酸阿法替尼中间体的制备方法
CN113121512B (zh) *	2019-12-30	2022-11-04	江苏晶立信医药科技有限公司	一种喹唑啉基丁烯酰胺类化合物的制备方法
KR20210106157A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제
KR20210106158A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 항암 치료 보조제
CN114315808A (zh) *	2020-10-10	2022-04-12	西安新通药物研究有限公司	一种高收率马来酸阿法替尼的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8618846D0 (en)	1986-08-01	1986-09-10	Smithkline Beckman Corp	Chemical process
JPS6442472A (en)	1987-08-10	1989-02-14	Kanebo Ltd	Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
GB9005014D0 (en) *	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
RU2043352C1 (ru) *	1991-07-01	1995-09-10	Пермский фармацевтический институт	2-пропил-3- (5-нитрофурфулиден)амино- 4(3н)-хиназолинон, проявляющий противостафилококковую и анальгетическую активность
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
ATE446955T1 (de)	1995-03-30	2009-11-15	Pfizer Prod Inc	Chinazolinone derivate
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
KR100437582B1 (ko)	1995-07-06	2004-12-17	노파르티스 아게	피롤로피리미딘및그들의제조방법
IL126351A0 (en)	1996-04-12	1999-05-09	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6262088B1 (en)	1998-11-19	2001-07-17	Berlex Laboratories, Inc.	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
ID29800A (id) *	1999-02-27	2001-10-11	Boehringer Ingelheim Pharma	Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
DE19911366A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CZ302365B6 (cs)	1999-06-21	2011-04-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg.	Bicyklické heterocyklické slouceniny, farmaceutický prostredek obsahující tyto slouceniny, jejich použití a zpusob výroby
US6627634B2 (en)	2000-04-08	2003-09-30	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20030158196A1 (en)	2002-02-16	2003-08-21	Boehringer Ingelheim Pharma Gmbh Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10063435A1 (de)	2000-12-20	2002-07-04	Boehringer Ingelheim Pharma	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de)	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20030225079A1 (en)	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es)	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
DK1948180T3 (da)	2005-11-11	2013-05-27	Boehringer Ingelheim Int	Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
ES2397181T3 (es)	2006-01-26	2013-03-05	Boehringer Ingelheim International Gmbh	Procedimiento para preparar derivados de quinazolina sustituida con aminocrotonilamino
SI2068880T1 (sl)	2006-09-18	2012-08-31	Boehringer Ingelheim Int	Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
UY31867A (es)	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
JP2012515184A (ja)	2009-01-14	2012-07-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	大腸がんの治療方法
LT2451445T (lt)	2009-07-06	2019-06-25	Boehringer Ingelheim International Gmbh	Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
WO2011069962A1 (en)	2009-12-07	2011-06-16	Boehringer Ingelheim International Gmbh	Bibw 2992 for use in the treatment of triple negative breast cancer
WO2012121764A1 (en)	2010-11-25	2012-09-13	Ratiopharm Gmbh	Novel salts and polymorphic forms of afatinib
WO2013052157A1 (en)	2011-10-06	2013-04-11	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
WO2015007206A1 (zh)	2013-07-16	2015-01-22	杭州普晒医药科技有限公司	阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
WO2016027243A1 (en)	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Novel solid state forms of afatinib dimaleate
CN104892584B (zh)	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
CN104926800A (zh)	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法

2003
- 2003-10-17 DE DE10349113A patent/DE10349113A1/de not_active Withdrawn
2004
- 2004-09-15 US US10/941,116 patent/US20050085495A1/en not_active Abandoned
- 2004-10-12 RS RS20060260A patent/RS53398B/en unknown
- 2004-10-12 ES ES04765927.1T patent/ES2440466T3/es not_active Expired - Lifetime
- 2004-10-12 PT PT47659271T patent/PT1678165E/pt unknown
- 2004-10-12 RS RS20130524A patent/RS60563B1/sr unknown
- 2004-10-12 RS YUP-2006/0260A patent/RS20060260A/sr unknown
- 2004-10-12 KR KR1020127003787A patent/KR101282812B1/ko active Protection Beyond IP Right Term
- 2004-10-12 HR HRP20160246TT patent/HRP20160246T4/hr unknown
- 2004-10-12 CA CA2759063A patent/CA2759063C/en not_active Expired - Lifetime
- 2004-10-12 ME MEP-2008-508A patent/ME00341B/me unknown
- 2004-10-12 MX MX2011004537A patent/MX338920B/es unknown
- 2004-10-12 DK DK12155662.5T patent/DK2508521T4/da active
- 2004-10-12 BR BR122013033343A patent/BR122013033343B8/pt active IP Right Grant
- 2004-10-12 NZ NZ547154A patent/NZ547154A/en unknown
- 2004-10-12 PL PL04765927T patent/PL1678165T3/pl unknown
- 2004-10-12 SI SI200432301T patent/SI2508521T2/sl unknown
- 2004-10-12 CN CN2004800305555A patent/CN1867564B/zh not_active Expired - Lifetime
- 2004-10-12 CA CA2541928A patent/CA2541928C/en not_active Expired - Lifetime
- 2004-10-12 EP EP12155662.5A patent/EP2508521B2/de not_active Expired - Lifetime
- 2004-10-12 ES ES12155662T patent/ES2563211T5/es not_active Expired - Lifetime
- 2004-10-12 SI SI200432099T patent/SI1678165T1/sl unknown
- 2004-10-12 EA EA200600604A patent/EA016624B1/ru active Protection Beyond IP Right Term
- 2004-10-12 CN CNA2008101664841A patent/CN101402631A/zh active Pending
- 2004-10-12 KR KR1020067009605A patent/KR101180752B1/ko active Protection Beyond IP Right Term
- 2004-10-12 MX MXPA06004076A patent/MXPA06004076A/es active IP Right Grant
- 2004-10-12 EP EP04765927.1A patent/EP1678165B1/de not_active Expired - Lifetime
- 2004-10-12 NZ NZ583049A patent/NZ583049A/en unknown
- 2004-10-12 WO PCT/EP2004/011378 patent/WO2005037824A2/de active Application Filing
- 2004-10-12 DK DK04765927.1T patent/DK1678165T3/da active
- 2004-10-12 SG SG200800279-2A patent/SG139743A1/en unknown
- 2004-10-12 UA UAA200605327A patent/UA91006C2/ru unknown
- 2004-10-12 HU HUE12155662A patent/HUE028254T2/en unknown
- 2004-10-12 BR BRPI0415424A patent/BRPI0415424B8/pt active IP Right Grant
- 2004-10-12 PL PL12155662.5T patent/PL2508521T5/pl unknown
- 2004-10-12 AU AU2004281938A patent/AU2004281938B2/en not_active Expired
- 2004-10-12 PT PT121556625T patent/PT2508521E/pt unknown
- 2004-10-12 JP JP2006534662A patent/JP4594317B2/ja not_active Expired - Lifetime
- 2004-10-12 UA UAA200810609A patent/UA91401C2/ru unknown
- 2004-10-14 MY MYPI2010002645A patent/MY155425A/en unknown
- 2004-10-14 UY UY28559A patent/UY28559A1/es active IP Right Grant
- 2004-10-14 MY MYPI20044237A patent/MY149921A/en unknown
- 2004-10-15 TW TW093131395A patent/TWI348468B/zh active
- 2004-10-15 AR ARP040103754A patent/AR046118A1/es not_active Application Discontinuation
- 2004-10-15 PE PE2004001000A patent/PE20050965A1/es active IP Right Grant
- 2004-10-15 TW TW099147116A patent/TWI373470B/zh active
- 2004-10-15 PE PE2010000135A patent/PE20100267A1/es not_active Application Discontinuation
2006
- 2006-03-16 ZA ZA200602234A patent/ZA200602234B/en unknown
- 2006-04-11 IL IL174951A patent/IL174951A/en active IP Right Grant
- 2006-04-17 EC EC2006006509A patent/ECSP066509A/es unknown
- 2006-05-15 NO NO20062181A patent/NO333971B1/no unknown
- 2006-07-14 US US11/457,622 patent/US8426586B2/en active Active
2007
- 2007-03-19 HK HK07102938.4A patent/HK1095817A1/xx not_active IP Right Cessation
2010
- 2010-06-21 JP JP2010140697A patent/JP5264830B2/ja not_active Expired - Lifetime
2011
- 2011-03-16 AU AU2011201171A patent/AU2011201171B2/en active Active
- 2011-11-10 IL IL216249A patent/IL216249A/en active IP Right Grant
2013
- 2013-05-10 NO NO20130663A patent/NO335103B1/no unknown
- 2013-12-09 CY CY20131101112T patent/CY1114866T1/el unknown
- 2013-12-20 HR HRP20131214TT patent/HRP20131214T1/hr unknown
2015
- 2015-02-04 UY UY0001035979A patent/UY35979A/es active IP Right Grant
2016
- 2016-03-11 CY CY20161100212T patent/CY1117279T1/el unknown

Also Published As

Publication number	Publication date
AU2011201171A1 (en)	2011-04-07
NO20062181L (no)	2006-05-15
BR122013033343B8 (pt)	2021-05-25
RS53398B (en)	2014-10-31
RS20130524A2 (en)	2014-06-30
SI2508521T1 (sl)	2016-03-31
JP5264830B2 (ja)	2013-08-14
PL2508521T3 (pl)	2016-06-30
UY28559A1 (es)	2005-05-31
ES2563211T5 (es)	2022-12-27
IL174951A0 (en)	2006-08-20
IL174951A (en)	2012-03-29
SI1678165T1 (sl)	2013-12-31
JP2010202668A (ja)	2010-09-16
EP2508521A3 (de)	2013-01-23
BR122013033343B1 (pt)	2020-10-13
SI2508521T2 (sl)	2022-11-30
EP1678165B1 (de)	2013-09-25
PT1678165E (pt)	2013-11-07
MX338920B (es)	2016-05-06
PE20050965A1 (es)	2005-12-19
BRPI0415424B8 (pt)	2021-05-25
RS20060260A (en)	2008-06-05
BRPI0415424A (pt)	2006-12-05
TW200526644A (en)	2005-08-16
AU2011201171B2 (en)	2012-02-09
US8426586B2 (en)	2013-04-23
JP4594317B2 (ja)	2010-12-08
CA2541928A1 (en)	2005-04-28
RS20130524A3 (en)	2015-08-31
PL1678165T3 (pl)	2014-03-31
CN1867564A (zh)	2006-11-22
ES2563211T3 (es)	2016-03-11
MXPA06004076A (es)	2006-06-27
CA2759063A1 (en)	2005-04-28
ME00341B (me)	2011-05-10
NZ583049A (en)	2011-08-26
BRPI0415424B1 (pt)	2019-01-22
UA91006C2 (ru)	2010-06-25
TWI373470B (en)	2012-10-01
HRP20160246T1 (hr)	2016-04-08
EP2508521B2 (de)	2022-09-07
KR20060120121A (ko)	2006-11-24
WO2005037824A2 (de)	2005-04-28
NO333971B1 (no)	2013-11-04
ZA200602234B (en)	2007-09-26
DK2508521T3 (en)	2016-03-29
HRP20160246T4 (hr)	2022-11-11
EP2508521B1 (de)	2015-12-30
EA016624B1 (ru)	2012-06-29
EP2508521A2 (de)	2012-10-10
UY35979A (es)	2016-09-30
WO2005037824A3 (de)	2005-07-21
US20050085495A1 (en)	2005-04-21
CA2759063C (en)	2012-04-17
NZ547154A (en)	2010-02-26
RS60563B1 (sr)	2020-08-31
CY1117279T1 (el)	2017-04-26
MEP50808A (en)	2011-02-10
UA91401C2 (en)	2010-07-26
KR101180752B1 (ko)	2012-09-10
SG139743A1 (en)	2008-02-29
HK1095817A1 (en)	2007-05-18
ES2440466T3 (es)	2014-01-29
CA2541928C (en)	2012-12-11
DK2508521T4 (da)	2022-10-03
EP1678165A2 (de)	2006-07-12
MY149921A (en)	2013-10-31
CN101402631A (zh)	2009-04-08
JP2007510624A (ja)	2007-04-26
HUE028254T2 (en)	2016-12-28
HRP20131214T1 (hr)	2014-01-31
ECSP066509A (es)	2006-10-10
KR101282812B1 (ko)	2013-07-05
PT2508521E (pt)	2016-03-31
PL2508521T5 (pl)	2023-03-27
AR046118A1 (es)	2005-11-23
IL216249A (en)	2015-05-31
MY155425A (en)	2015-10-15
CN1867564B (zh)	2011-06-08
US20070027170A1 (en)	2007-02-01
KR20120037987A (ko)	2012-04-20
IL216249A0 (en)	2011-12-29
DK1678165T3 (da)	2013-12-09
TW201118086A (en)	2011-06-01
EA200600604A1 (ru)	2006-10-27
NO335103B1 (no)	2014-09-15
CY1114866T1 (el)	2016-12-14
AU2004281938A1 (en)	2005-04-28
AU2004281938B2 (en)	2011-04-14
DE10349113A1 (de)	2005-05-12
NO20130663L (no)	2006-05-15
PE20100267A1 (es)	2010-04-21

Publication	Publication Date	Title
TWI348468B (en)	2011-09-11	Process for preparing amino crotonyl compounds
IL172331A0 (en)	2011-08-01	Processes for preparing 3-benzazepines
PL375316A1 (en)	2005-11-28	Process for preparing certain pyrrolotriazine compounds
HRP20150163T1 (en)	2015-03-27	Process for the preparation of n-substituted 2-cyanopyrrolidines
MY137678A (en)	2009-02-27	Process for preparing formaldehyde
SG137677A1 (en)	2007-12-28	Improved process for preparing polyalkenylsuccinimides
EG23557A (en)	2006-06-05	Process for preparing aripiprazole
HUP0500037A3 (en)	2010-01-28	Process for preparing insulin compounds
EP1612274A4 (en)	2011-05-11	PROCESS FOR PURIFYING DIFRUCTOSE-DIANHYDRIDE III
HK1078863A1 (en)	2006-03-24	Process for preparing (s)-pantoprazole
IL172765A0 (en)	2006-04-10	Improved process for preparing alpha-polymorphic eletriptan hydrobromide
EP1683776A4 (en)	2007-08-29	METHOD FOR PRODUCING A RADIOACTIVE, FLUORMARKED COMPOUND
IL183804A0 (en)	2007-09-20	Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
AU2003240491A8 (en)	2003-12-19	Process for preparing vinylaromatic compounds
GB2412373B (en)	2007-02-21	Process for preparing guggulsterones
PL1698619T3 (pl)	2014-04-30	Sposób wytwarzania pochodnej 2-halogenobenzamidu
AU2003243574A8 (en)	2003-12-31	Process for preparing n-protected beta-amino aldehyde compounds
GB0522075D0 (en)	2005-12-07	Process for preparing almodipline mesylate monohydrate
PL374000A1 (en)	2005-09-19	Improved process for hydroxyazapirones
HU0300167D0 (en)	2003-03-28	Process for alginat obtaining from alginit
SI1534705T1 (sl)	2006-12-31	Postopek priprave zolmitriptanskih spojin
IL164340A0 (en)	2005-12-18	Process for preparing gabapentin
GB2401361B (en)	2007-03-28	Improved process for brick manufacture
SI1599442T1 (sl)	2007-12-31	Postopek za pripravo gama-cihalotrina
GB0311265D0 (en)	2003-06-18	Process for preparing chiral amino nitriles